Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Alberta

$25,000.00

Identification of early stage lung cancer biomarkers via metabolomics

EF 2016-17

Résumé
Metabolomic Technologies Inc. (MTI), an Edmonton based company, is seeking to extend the inventory oftheir cancer diagnostic kits to lung cancer. Lung cancer has the highest mortality rate among neoplasticdiseases, and early detection can significantly lower both mortality and morbidity. The current standardscreening method for lung cancer is Low Dose Computed Tomography (LDCT). However, LDCT suffers froma 96% false positive rate, imposing a high cost to the health service system, with little benefit. An adjunctlow-cost screening test using blood or urine biomarkers, could help to reduce the rate of LDCT false positives,improving early stage lung cancer diagnosis. We will screen a series of urine samples in the hopes ofdeveloping a panel of potential biomarkers for a fast, non-invasive and low-cost ""metabolomics""-based tosupplement (or replace) LDCT. Metabolomics studies allow comprehensive characterization of metabolites inbiological specimens such as serum, urine, sputum, tissue, etc. ""Fluid biopsies"" such as urine, serum and CSFcan give an advantage of fast screening and higher patient compliance due to their non-invasive nature. Toidentify an appropriate panel of urinary biomarkers, a suite of analyses comprising GC?GC-TOFMS, LC-MSand NMR techniques will be utilized, and methods to integrate their data developed. Using these threetechniques in one study will represent the most comprehensive urinary metabolomics study for lung cancerbiomarkers to date. We anticipate that up to 600 metabolites will be identified and quantified in this study.Urine samples from 35 early-stage lung cancer patients and 35 controls will be used for metabolomic profiling.An advanced computer algorithm will be also developed for optimizing the assay performance. The identifiedbiomarkers will be tested on a separate set of 40 samples (20 control and 20 diseased) and the results will bereported to MTI, for further assay development and commercialization.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
505302-2016
Name nom
Harynuk, James
Department département
Chemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3503
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Separation methods
Research subject fr
Méthodes de séparation
Partie
1
Nb partie
1
Application title
Identification of early stage lung cancer biomarkers via metabolomics
Keyword
NSERC
Application summary
Metabolomic Technologies Inc. (MTI), an Edmonton based company, is seeking to extend the inventory oftheir cancer diagnostic kits to lung cancer. Lung cancer has the highest mortality rate among neoplasticdiseases, and early detection can significantly lower both mortality and morbidity. The current standardscreening method for lung cancer is Low Dose Computed Tomography (LDCT). However, LDCT suffers froma 96% false positive rate, imposing a high cost to the health service system, with little benefit. An adjunctlow-cost screening test using blood or urine biomarkers, could help to reduce the rate of LDCT false positives,improving early stage lung cancer diagnosis. We will screen a series of urine samples in the hopes ofdeveloping a panel of potential biomarkers for a fast, non-invasive and low-cost ""metabolomics""-based tosupplement (or replace) LDCT. Metabolomics studies allow comprehensive characterization of metabolites inbiological specimens such as serum, urine, sputum, tissue, etc. ""Fluid biopsies"" such as urine, serum and CSFcan give an advantage of fast screening and higher patient compliance due to their non-invasive nature. Toidentify an appropriate panel of urinary biomarkers, a suite of analyses comprising GC?GC-TOFMS, LC-MSand NMR techniques will be utilized, and methods to integrate their data developed. Using these threetechniques in one study will represent the most comprehensive urinary metabolomics study for lung cancerbiomarkers to date. We anticipate that up to 600 metabolites will be identified and quantified in this study.Urine samples from 35 early-stage lung cancer patients and 35 controls will be used for metabolomic profiling.An advanced computer algorithm will be also developed for optimizing the assay performance. The identifiedbiomarkers will be tested on a separate set of 40 samples (20 control and 20 diseased) and the results will bereported to MTI, for further assay development and commercialization.